Key facts
| Company | Happiest Baby, Inc. |
|---|---|
| FDA office | Center for Devices and Radiological Health |
| Letter date | June 15, 2026 |
| Subject / product | Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device |
| CFR citations | FDA Warning Letter |
| Response due | 15 working days from receipt (standard FDA warning-letter requirement) |
| Reference / source ID | happiest-baby-inc-718306-06152026 |
What happens next
Happiest Baby, Inc. is expected to respond to FDA in writing, typically within 15 working days of the letter date, describing the specific corrective and preventive actions taken or planned for each violation cited. FDA reviews that response and any follow-up evidence, and can conduct a re-inspection to confirm the corrections were actually made. If FDA judges the response inadequate, or the underlying conditions serious enough, further action can follow, including product seizure, injunction, import alert, or civil penalties; many Warning Letters are resolved through corrective action alone. This page reflects the Warning Letter as issued and will not reflect any subsequent correction unless FDA publishes a follow-up record. FDA issues Warning Letters after an inspection or other review when it believes a firm has significantly violated FDA regulations; the letter itself is a notice, not a final adjudication.
Violations explained
FDA Warning Letter — Violations FDA cited at Happiest Baby, Inc.
WARNING LETTER Happiest Baby, Inc. MARCS-CMS 718306 — June 15, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Medical Devices Recipient: Recipient Name Dr. Harvey Karp Recipient Title Chief Executive Officer Happiest Baby, Inc. 11390 W. Olympic Blvd. Ste. 450 Los Angeles , CA 90064 United States (b)(4) Issuing Office: Center for Devices and Radiological Health United States WARNING LETTER CMS #718306 June 15, 2026 Dear Dr. Karp: During an inspection of your firm located in Los Angeles, CA from July 21, 2025 through July 25, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the SNOO Smart Sleeper and the SNOO Hospital Bundle. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. We received responses from Dr. Harvey Karp, CEO, dated August 15, 2025, and February 26, 2026, concerning the observations and discussion items from the inspection. Unapproved Device Violations Our inspection and review of your website and marketing materials revealed that the SNOO Smart Sleeper and the SNOO Hospital Bundle are adulterated under section 501(f)(1) of the Act, 21 U.S.C. § 351(f)(1), and misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o). The SNOO Smart Sleeper and SNOO Hospital Bundle are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g), for the devices as described and marketed. The SNOO Smart Sleeper and SNOO Hospital Bundle are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices without submitting to FDA a notice or other information respecting the significant changes or modifications that your firm made to the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). The SNOO Smart Sleeper was authorized under DEN210039 with the following indications: “The SNOO Smart Sleeper bassinet plus the SNOO Sleep Sack are jointly intended to facilitate a supine position during sleep. Infants who are placed in a supine sleep position are at lower risk of SIDS/SUID. The device is intended for home use by caregivers of infants from birth to 6 months of age, who are not yet able to roll over consistently.” In addition, the Device Description section of FDA’s Decision Summary for DEN210039 specifies the following: “The SNOO Sleep Sack is a cotton swaddle with fixed wings made of woven cotton fabric that extend to the right and left of the infant's body. Three sizes of sleep sacks (small 5-12 lbs, medium 12-18 lbs, and large 18-25 lbs) are provided with each bassinet to accommodate the growing baby.” However, there is evidence that your firm has significantly changed or modified the SNOO Smart Sleeper by introducing two new sizes of sleep sacks, as described in more detail below. 1. X-Small Sleep Sack Our inspection and review of your firm’s website, https://www.happiestbaby.com (last reviewed on May 7, 2026), revealed that your firm is currently distributing an X-Small Sleep Sack for infants 4-8 lbs. 1 When FDA granted your De Novo request, it authorized use of the SNOO bassinet with three sizes of sleep sacks (Small 5-12 lbs, Medium 12-18 lbs, and Large 18-25 lbs). Your new X-Small Sleep Sack has smaller dimensions than any of the sleep sacks that
Happiest Baby, Inc.’s FDA history
Argus HQ has recorded 1 total FDA action tied to Happiest Baby, Inc.: 1 warning letter, 0 recalls, 0 approval records, and 0 Form 483 inspection citations.
Full letter text
Read the rest of the full text
Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- What is an FDA Warning Letter?
- An FDA Warning Letter notifies a company that FDA believes it has significantly violated FDA regulations and that prompt corrective action is required. It is issued after an inspection, sample analysis, or other FDA review, and is a notice -- not a final legal determination and not itself a penalty.
- Does this Warning Letter mean Happiest Baby, Inc. violated the law?
- FDA's letter documents violations it believes it found at Happiest Baby, Inc.. A Warning Letter is not a final adjudication of guilt; the company has an opportunity to respond and correct the cited issues, and many Warning Letters are resolved without further enforcement once FDA confirms adequate correction.
- What happens after a Warning Letter is issued?
- The firm generally must respond in writing within 15 working days; FDA reviews the response and can escalate to seizure, injunction, or import alert if it judges the response inadequate. Many Warning Letters are resolved through corrective action alone.
Get the next warning letter in this therapeutic area before your team hears about it secondhand.
Weekly briefing, free. Upgrade any time for daily or real-time delivery.
Related enforcement actions
Full FDA history for Happiest Baby, Inc.- Warning letter (recent): Med Shop Inc / www.medshopinc.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): ketaminetroches.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketdaxandrugs / www.ketdaxandrugs.org — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Legit Ketamine Suppliers / www.legitketaminesuppliers.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketamine Store / www.ketaminestore.org — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Buy Keta Online / www.buyketaonline.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): Ketamine Troche Store / www.ketaminetrochestore.com — Unapproved New Drugs/Misbranded (2026-06-23) →
- Warning letter (recent): All Ketamine HCL / www.allketaminehcl.com — Unapproved New Drugs/Misbranded (2026-06-23) →
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). June 15, 2026 FDA Warning Letter: Happiest Baby, Inc. Cited for Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device. Digital Empire LLC. Retrieved from https://argushq.ai/warning-letter/happiest-baby-718306-2026-06-15
"June 15, 2026 FDA Warning Letter: Happiest Baby, Inc. Cited for Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/warning-letter/happiest-baby-718306-2026-06-15.
Argus HQ Research. "June 15, 2026 FDA Warning Letter: Happiest Baby, Inc. Cited for Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/warning-letter/happiest-baby-718306-2026-06-15.
@misc{argushq_argushq_ai_warning_letter_happiest_baby_718306_2026_06_15_2026,
title = {June 15, 2026 FDA Warning Letter: Happiest Baby, Inc. Cited for Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/warning-letter/happiest-baby-718306-2026-06-15},
note = {Accessed: July 13, 2026}
}Source: FDA.gov — Warning Letters ↗

